Itraconazole Capsules 65MG (Supra Bioavailable Formulation) – TRIACON 65 SB Capsules

Itraconazole Capsules 65MG (Supra Bioavailable Formulation) – TRIACON 65 SB Capsules

  • Home
  • -
  • Product
  • -
  • Itraconazole Capsules 65MG (Supra Bioavailable Formulation) – TRIACON 65 SB Capsules

Itraconazole Capsules 65MG (Supra Bioavailable Formulation) – TRIACON 65 SB Capsules

1,998.00

Itraconazole Capsules 65mg (Supra Bioavailable Formulation)
10*10 Alu-Alu

Description

TRIACON 65 SB Capsules – Targeted Antifungal Therapy with Enhanced Strength.

TRIACON 65 SB Capsules (Serba Technology) – Itraconazole 65 mg Capsules is a triazole antifungal agent that blocks the synthesis of ergosterol, an essential component of fungal cell membranes, resulting in disruption of fungal growth and cell death. It is widely used for systemic and superficial fungal infections, including dermatophytosis, onychomycosis, and vulvovaginal candidiasis caused by organisms such as Candida, Aspergillus, and Histoplasma.

Key Benefits of Itraconazole Capsules 65MG (Supra Bioavailable Formulation) – TRIACON 65 SB Capsules
Broad-Spectrum Efficacy – Active against both superficial and systemic fungal infections.
Effective in Resistant Strains – A reliable option where fluconazole or terbinafine resistance is noted.
Convenient Oral Formulation – Capsule form ensures systemic absorption and ease of administration.

Recommended by specialists:
👨‍⚕️ Dermatologists – for resistant fungal infections of the skin, scalp, and nails.
👩‍⚕️ Gynecologists – for recurrent or chronic vulvovaginal candidiasis.

Indications
✅ Systemic fungal infections (aspergillosis, histoplasmosis, blastomycosis)
✅ Dermatophyte infections (tinea corporis, tinea pedis, tinea cruris)
✅ Onychomycosis (fungal nail infection)
✅ Oropharyngeal, esophageal, and vulvovaginal candidiasis
✅ Pityriasis versicolor

Reviews

There are no reviews yet.

Be the first to review “Itraconazole Capsules 65MG (Supra Bioavailable Formulation) – TRIACON 65 SB Capsules”

Your email address will not be published. Required fields are marked *